Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns
News Summary:
- New line of GTxResolve™ Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of cell & gene-based therapeutics.
- Reduces problematic non-specific binding, minimizes mobile phase method development challenges, and provides higher throughput separation efficiency.
- Increases resolution up to 50% for components present within mRNA, lipid nanoparticles (LNP), and viral vectorsi for more confident measurement of critical quality attributes tied to safety, stability, and potency.
"The pipeline of nucleic acid therapeutics continues to grow at a double-digit paceii as developers strive to submit new investigational drug filings and complete their first in-human trials. The new Waters GTxResolve Premier SEC Columns supports the growing demand for mRNA, lipid nanoparticle, and viral vector-based therapies with columns that are more robust and provide higher efficiency," said
"RNA lipid nanoparticles are analytically complex therapeutics. Traditional batch analysis techniques only discern information of the drug product as a whole and fail to detect the subtle difference in particle size populations and corresponding compositional variations therein," said
GTxResolve Premier SEC Columns are engineered to reduce problematic non-specific binding, minimize mobile phase method development challenges, and provide higher throughput separation efficiency. They offer up to 50% increases in resolution for components present within mRNA, LNPs, and viral vector samples. They offer low out-of-the-box secondary interactionsi, iii, iv, enabling robust multi-attribute platform methods and more than 2x improvements in sample consumption, run times, and sensitivity versus existing 5 and 10 µm HPLC columns.v
Waters GTxResolve Premier SEC 1000Å 3 µm Columns are now available globally, alongside Waters previously released GTxResolve Premier BEH SEC 450Å 2.5 µm Columns. These column technologies are quality control batch-tested with an industry-first use of both protein and nucleic acid test mixtures to ensure new levels of separation reproducibility.
Additional Resources
- Learn more at www.waters.com/GTxResolveSEC
- Register for our on-demand global webinar
- Attend our Presentation at the 27th Annual ASGCT Meeting in
Baltimore, MD :Exhibit Hall Theater -May 8 th4:30 PM - Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters, GTxResolve, and MaxPeak are trademarks of
Contact:
Senior Public Relations Manager, Corporate Communications
janice_foley@waters.com
+1.617.823.5555
_______________________________ |
|
|
|
|
|
|
i For 1000Å 3 µm GTxResolve Premier SEC columns versus conventional steel 5 and 10 µm columns |
||||||
ii +11% for Phase I cell & gene therapy programs according to |
||||||
iii "Size Exclusion and Ion Exchange Chromatographic Hardware Modified with a Hydrophilic Hybrid Surface." Anal. Chem. 2022, 94, 7, 3360–3367. |
||||||
iv "Investigating the secondary interactions of packing materials for size-exclusion chromatography of therapeutic proteins." |
||||||
v "Fast and efficient size exclusion chromatography of adeno associated viral vectors with 2.5 micrometer particle low adsorption columns." |
View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-accelerates-the-development-of-gene-based-therapeutics-with-new-gtxresolve-premier-sec-columns-302122473.html
SOURCE